ArticleLancet regional health. Americas2025
Validation of VaxEstim, a Bayesian model for rapid estimation of measles-mumps-rubella vaccination coverage at outbreak onset: a cross-sectional study.
Article in Lancet regional health. Americas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Background: Accurate estimation of vaccination coverage at the onset of an outbreak is critical for guiding timely public health responses. Conventional methods often rely on delayed or incomplete data that obscure immunity gaps. During the 2022-2023 central Ohio measles outbreak, Columbus Public Health estimated measles-mumps-rubella ( Methods: We conducted a cross-sectional validation study using electronic medical records from the PCN of 133,476 children <15 years of age. This cohort included 9864 children of Somali descent residing in Columbus, who comprised the previously defined outbreak-exposed population. Two-dose MMR coverage was defined as ≥2 valid doses by the outbreak onset date of October 8, 2022. VaxEstim's predicted coverage was compared with observed coverage in this group. Findings: Observed two-dose MMR coverage among the outbreak-exposed population was 42.4% (4181 of 9864; 95% CI 41.4-43.4), compared with VaxEstim's early-phase prediction of 53.0% (95% CrI 21.0-77.0). The wide credible interval reflects uncertainty typical of early outbreak phases. Model performance showed a mean absolute error of 0.106 and a mean squared error of 0.0113. Interpretation: This study externally validates the VaxEstim prediction against observed coverage in this outbreak-exposed population. The model accurately predicted substantial underimmunisation, underscoring its potential to guide rapid, targeted public health action. Funding: National Institute of General Medical Sciences, National Institutes of Health; National Science Foundation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.